The neurologic learning disability syndrome.
D000856:Anorexia Nervosa / Q000209:etiology; D001007:Anxiety / Q000209:etiology; D001288:Attention; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D001925:Brain Damage, Chronic / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D006948:Hyperkinesis / Q000150:complications; D007099:Imipramine / Q000008:administration & dosage / Q000009:adverse effects; D007802:Language; D007806:Language Disorders / Q000150:complications; D007859:Learning Disabilities / Q000145:classification / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D008568:Memory; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects; D009043:Motor Activity; D010348:Patient Care Team; D010468:Perceptual Disorders / Q000150:complications; D011613:Psychotherapy; D012893:Sleep Wake Disorders / Q000209:etiology
D008774:Methylphenidate; D007099:Imipramine; D003913:Dextroamphetamine